Pfizer Inc. (NYSE:PFE) study results have demonstrated its investigational 4-antigen Staphylococcus aureus candidate vaccine (SA4Ag) showed rapid rises in functional antibody titers against S. aureus that were maintained through at least 12 months. The vaccine was well tolerated in the 456 healthy adults 18 to 64 years old who randomly received a single intramuscular injection. Pfizer Inc. (NYSE:PFE) will present data from the Phase 1/Phase 2 study evaluating the safety, tolerability and immunogenicity at IDWeek 2014, being held this week in Philadelphia, Pennsylvania.The SA4Ag vaccine candidate (PF-06290510), currently in Phase 2 clinical trials, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in February 2014. "Pfizer now has three innovative prophylactic investigational vaccine candidates with the potential to prevent serious diseases -- meningococcal group B (MnB), S. aureus and Clostridium difficile (C. difficile) -- that have been granted Fast Track designation by the FDA," said Susan Silbermann, president and general manager for Pfizer Vaccines.Trina Solar Limited (ADR) (NYSE:TSL), the maker of photovoltaic modules said it signed a share-purchase agreement on Sept. 30 to sell its 10.6 megawatt PV power plant located in Trehawke, UK to funds managed by Foresight Group LLP. This is the first of two Trina Solar UK projects that connected to the grid in Q1 2014, the company noted. Financial terms of the deal weren't disclosed."Successful completion of this sale will allow us to redeploy resources on other projects and to further expand our pipeline in the UK," said Jifan Gao, CEO of Trina Solar Limited (ADR) (NYSE:TSL)."We currently have an additional 49.9MW project under construction in the UK expected to be completed in Q1 2015, which has attracted the interest of several potential buyers."Regado Biosciences Inc (NASDAQ:RGDO) said it has appointed its president Michael A. Metzger to the additional post of chief executive officer replacing David J. Mazzo, who has resigned. "Michael has a proven track record of effectively growing companies, and his extensive business development and transactional experience is ideal as Regado focuses on evaluating strategic alternatives to optimize value for shareholders," Regado Biosciences Inc (NASDAQ:RGDO) Chairman Dennis Podlesak said.Metzger joined Regado in December 2013 and has nearly 20 years of experience within the life sciences sector. He was previously chief operating officer at Mersana Therapeutics. The company gave no reason for Mazzo's resignation. The company last month said it was cutting about 60% of its workforce and starting a strategic review of its business after terminating a trial of its lead drug candidate. The shares closed at $1.06 on Thursday near the bottom of a 52-week spread of $0.96 - $14.10.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
